Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$81.68 USD

81.68
1,253,027

+2.56 (3.24%)

Updated May 31, 2024 04:00 PM ET

After-Market: $82.69 +1.01 (1.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

HealthEquity (HQY) Upgraded to Buy: What Does It Mean for the Stock?

HealthEquity (HQY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Premier, Inc. (PINC) Beats Q4 Earnings and Revenue Estimates

Premier, Inc. (PINC) delivered earnings and revenue surprises of 1.67% and 1.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

XpresSpa Group, Inc. (XSPA) Reports Q2 Loss, Tops Revenue Estimates

XpresSpa Group, Inc. (XSPA) delivered earnings and revenue surprises of 20% and 1.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Lags Revenue Estimates

Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 5% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ICLR vs. HQY: Which Stock Should Value Investors Buy Now?

ICLR vs. HQY: Which Stock Is the Better Value Option?

Has Elevance Health, Inc. (ELV) Outpaced Other Medical Stocks This Year?

Here is how Elevance Health (ELV) and HealthEquity (HQY) have performed compared to their sector so far this year.

What's in Store for West Pharmaceutical (WST) in Q2 Earnings?

West Pharmaceutical's (WST) second-quarter results are likely to reflect strength in the Proprietary Products business.

Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?

Ecolab's (ECL) second-quarter results are likely to reflect continued strength in its Global Industrial segment.

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

Stryker's (SYK) second-quarter results are likely to reflect strong segmental performances. However, the resurgence of COVID-19 infections is likely to have hurt sales growth.

Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?

Here is how HealthEquity (HQY) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.

Why Is HealthEquity (HQY) Down 10% Since Last Earnings Report?

HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why HealthEquity (HQY) is Poised for a Turnaround After Losing 7.7% in 4 Weeks

HealthEquity (HQY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why You Should Hold on to Accuray (ARAY) Stock For Now

Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.

Catalent (CTLT) Inks Deal With MigVax for Oral COVID-19 Vaccine

Catalent's (CTLT) latest agreement is expected to significantly boost global COVID-19 vaccination drives.

BD's (BDX) New Tie-Up to Develop Detection Kit for Monkeypox

BD's (BDX) partnership with CerTest is expected to aid in advancing the understanding of the monkeypox virus' global spread.

BD (BDX) to Expand Base in Pharmacy Automation With New Buyout

BD's (BDX) buyout of Parata Systems is expected to advance its 2025 strategy to accelerate innovation in smart, connected care and enabling new care settings.

HealthEquity (HQY) Q1 Earnings Lag Estimates, FY23 View Up

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust segmental revenues, in the first quarter of fiscal 2023.

Here's Why You Should Hold on to Avanos (AVNS) Stock For Now

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.

HealthEquity (HQY) Q1 Earnings Miss Estimates

HealthEquity (HQY) delivered earnings and revenue surprises of -3.57% and 1.46%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?

Assure Holdings Corp. (IONM) Reports Q1 Loss, Misses Revenue Estimates

Assure Holdings Corp. (IONM) delivered earnings and revenue surprises of -216.67% and 27.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

InnovAge Holding Corp. (INNV) Reports Q3 Loss, Tops Revenue Estimates

InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -300% and 5.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) Q1 Earnings Beat Estimates

Viatris (VTRS) delivered earnings and revenue surprises of 14.81% and 0.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

HealthEquity (HQY) Q4 Earnings Lag Estimates, Margins Down

HealthEquity (HQY) witnesses solid growth in HSAs, along with recording robust Custodial and Interchange revenues, in the fourth quarter of fiscal 2022.

HealthEquity (HQY) Q4 Earnings Miss Estimates

HealthEquity (HQY) delivered earnings and revenue surprises of -4.76% and 2.02%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?